ProShares Ultra NASDAQ Biotechnology
BIB
BIB
41 hedge funds and large institutions have $34.8M invested in ProShares Ultra NASDAQ Biotechnology in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.97% more ownership
Funds ownership: 6.74% → 8.7% (+2%)
5% less call options, than puts
Call options by funds: $13.2M | Put options by funds: $13.9M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
41
Holding in Top 10
–
Calls
$13.2M
Puts
$13.9M
Top Buyers
| 1 | +$6.93M | |
| 2 | +$4M | |
| 3 | +$3.45M | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.14M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$342K |
Top Sellers
| 1 | -$5.37M | |
| 2 | -$1.24M | |
| 3 | -$1.16M | |
| 4 |
SAM
Stansberry Asset Management
Westlake,
Texas
|
-$370K |
| 5 |
HF
HRT Financial
New York
|
-$258K |